List of Excipients in Branded Drug FYCOMPA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eisai Inc	FYCOMPA	perampanel	62856-272	FERRIC OXIDE RED
Eisai Inc	FYCOMPA	perampanel	62856-272	FERRIC OXIDE YELLOW
Eisai Inc	FYCOMPA	perampanel	62856-272	HYPROMELLOSES
Eisai Inc	FYCOMPA	perampanel	62856-272	LACTOSE MONOHYDRATE
Eisai Inc	FYCOMPA	perampanel	62856-272	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
Eisai Inc	FYCOMPA	perampanel	62856-272	MAGNESIUM STEARATE

Fycompa Excipient Strategy and Commercial Opportunities for Perampanel

Last updated: August 9, 2026

Fycompa, Takeda’s branded perampanel product, is an oral antiseizure medicine approved in the U.S. as tablets and an oral suspension. Its excipient strategy is commercially relevant because perampanel has low aqueous solubility, a long half-life, dose-dependent central nervous system adverse effects, and a patient population that includes children and patients with swallowing difficulties. The strongest opportunities are generic tablets, differentiated liquid delivery, pediatric-friendly dosage forms, and formulation improvements that reduce dosing errors and improve adherence.

What dosage forms and excipients does Fycompa use?

Fycompa is available as immediate-release film-coated tablets in 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg strengths, and as a 0.5 mg/mL oral suspension. The FDA-approved product uses conventional solid-dose excipients and a structured aqueous suspension system.[1]

Fycompa tablet excipients

The tablet core uses excipients associated with direct compression or dry granulation, including:

Functional role	Reported or label-associated excipient
Diluent	Lactose monohydrate
Binder or compression aid	Povidone
Disintegrant or processing aid	Low-substituted hydroxypropyl cellulose
Lubricant	Magnesium stearate
Film former	Hypromellose
Plasticizer or coating aid	Macrogol, also called polyethylene glycol
Opacifier	Titanium dioxide
Colorants	Iron oxides, depending on tablet strength
Anti-tacking or coating aid	Talc

The tablet platform is commercially conventional. Its value lies less in a complex delivery system than in dose scalability, acceptable manufacturability, and a broad six-strength product range.

Fycompa oral-suspension excipients

The oral suspension is designed to maintain perampanel in a uniformly redispersible liquid vehicle. Label-associated excipients include:

Functional role	Excipient
Suspending and viscosity system	Microcrystalline cellulose and carmellose sodium
Rheology modifier	Xanthan gum
Humectant and mouthfeel agent	Glycerol
Sweetener and bulk agent	Sorbitol
Wetting or dispersion aid	Poloxamer 188
Preservative	Sodium benzoate
pH adjustment	Citric acid
Vehicle	Purified water

The formulation must support dose uniformity at low volumes, physical stability during storage, acceptable palatability, preservative effectiveness, and accurate administration through the supplied dosing device.[1]

Why is perampanel formulation technically challenging?

Perampanel is a small-molecule AMPA receptor antagonist with limited water solubility. A formulation must provide reproducible exposure without relying on a high-energy manufacturing process or a large quantity of surfactant.

The main technical risks are:

1. Sedimentation and caking in the oral suspension.
2. Dose nonuniformity after incomplete shaking.
3. Poor wetting of perampanel particles.
4. Taste and mouthfeel problems in pediatric patients.
5. Chemical or microbial instability in the aqueous vehicle.
6. Variability from dosing syringes, cups, or household spoons.
7. Food effects and administration inconsistency.
8. Overexposure caused by dosing errors in a drug with CNS-related adverse effects.

Fycompa’s suspension addresses these issues through a cellulose-based suspension system, xanthan gum, a nonionic wetting agent, a preservative, and a structured dosing device. A competing product would need to demonstrate equivalent exposure and reliable dose delivery while also managing palatability and physical stability.

What formulation patents and intellectual-property barriers protect Fycompa?

Perampanel’s intellectual-property estate has historically included composition-of-matter, therapeutic-use, formulation, and manufacturing-related rights. The commercial importance of each category differs.

Composition-of-matter patents

The earliest perampanel patents cover substituted pyridone compounds and related chemical classes. These patents formed the principal barrier to generic perampanel during the initial product life cycle. Composition patents generally create the strongest exclusionary position because a conventional generic cannot avoid the active-ingredient claim by changing excipients.

Method-of-use patents

Perampanel is approved for:

• Adjunctive treatment of partial-onset seizures in patients at least 4 years old.
• Adjunctive treatment of primary generalized tonic-clonic seizures in patients at least 12 years old, depending on jurisdiction and label version.

Method-of-use claims may cover seizure treatment, dose ranges, titration schedules, or particular patient populations. Their value depends on claim scope and whether a generic can launch with a label that omits the protected indication.

Formulation patents

Formulation claims may cover:

• An aqueous suspension containing perampanel.
• Specific suspending agents or viscosity ranges.
• Particle-size distributions.
• Wetting agents or surfactant systems.
• Preservative combinations.
• pH ranges.
• Dosing devices and administration methods.
• Stability profiles over the labeled shelf life.

Formulation patents are most important for liquid competitors and 505(b)(2) applicants. They are less important to a conventional tablet generic if the tablet uses a materially different excipient composition and does not practice the asserted claims.

Manufacturing and process patents

Process patents may cover crystallization, particle-size control, polymorph selection, purification, or granulation conditions. These rights can create practical barriers even when a product patent has expired. A generic manufacturer must establish a reproducible active pharmaceutical ingredient process and control solid-state attributes that affect dissolution and bioavailability.

What is the FDA regulatory status of Fycompa?

The FDA approved Fycompa in 2012 for partial-onset seizures and later expanded its use to primary generalized tonic-clonic seizures. The product has tablet and oral-suspension presentations. The oral suspension is particularly relevant to pediatric and dysphagia markets.[1]

FDA regulatory pathway for competing products

A competitor can pursue several routes:

Product concept	Likely U.S. pathway	Commercial implication
Conventional perampanel tablet	ANDA under section 505(j)	Lowest regulatory burden if bioequivalence and pharmaceutical equivalence are established
Perampanel oral suspension equivalent	ANDA, subject to product-specific requirements	Requires close control of suspension quality and dosing performance
Improved pediatric liquid	505(b)(2) or ANDA, depending on differences	May support differentiated labeling or formulation claims
Orally disintegrating tablet	505(b)(2) or ANDA	Can target swallowing difficulty and adherence
Sprinkle or multiparticulate dosage form	Usually 505(b)(2) if materially different	May support pediatric and dysphagia positioning
New fixed-dose combination	505(b)(2) or new drug application	Higher clinical and regulatory requirements

Because perampanel is a small molecule, biosimilar competition is not relevant. The competitive issue is generic and reformulated small-molecule entry.

What is the Orange Book status of Fycompa?

The Orange Book identifies FDA-approved products and relevant patent and exclusivity information. Fycompa’s listed patents and exclusivity periods must be reviewed against the current Orange Book and FDA patent-listing records before a launch decision.[2]

For a generic applicant, the main questions are:

• Which patents are currently listed for each Fycompa dosage form?
• Which listed patents cover tablets, oral suspension, or both?
• Are any listed patents method-of-use patents subject to a section viii statement?
• Have listed patents expired, been delisted, or been litigated?
• Is pediatric exclusivity attached to any listed patent or regulatory exclusivity period?
• Does the generic product require a Paragraph IV certification?

The patent analysis must be product-specific. A tablet ANDA may face a different set of listed patents from a liquid product. A generic suspension that uses a similar excipient architecture may create greater infringement exposure than a tablet that uses a distinct formulation.

When does Fycompa lose exclusivity?

Fycompa’s core small-molecule exclusivity has been subject to patent expiration and potential pediatric extensions. Regulatory exclusivity and patent exclusivity must be separated.

Protection type	Relevance to Fycompa
New chemical entity exclusivity	Historically applied after the original FDA approval period
Patent term	Depends on the specific perampanel patent, priority date, patent-term adjustment, and any extension
Pediatric exclusivity	May add six months to qualifying periods if FDA requirements are satisfied
Orphan exclusivity	Not the principal commercial protection for the broad Fycompa product
Listed method-of-use patents	Can affect label carve-outs and launch timing
Formulation patents	More relevant to suspension or differentiated dosage-form entry

Public company filings have historically described generic competition and loss-of-exclusivity risk as material to Takeda’s product portfolio. Fycompa revenue is reported within Takeda’s product portfolio rather than always being disclosed as a standalone line item, which limits precise public revenue attribution.[3]

Which companies are challenging Fycompa?

Generic competition is expected to come from companies with established CNS portfolios, ANDA capabilities, and access to controlled or high-complexity oral dosage-form manufacturing. Potential competitors include large generic manufacturers and specialty generic companies that can support both tablet and liquid development.

A definitive list of active Paragraph IV challengers must be taken from current FDA ANDA litigation records, court dockets, and the Orange Book. Paragraph IV status can change through settlement, dismissal, covenant-not-to-sue agreements, or conversion to a noninfringement or invalidity dispute.

How does a Paragraph IV challenge affect launch timing?

A first filer that submits a valid Paragraph IV certification may qualify for 180 days of generic exclusivity under applicable FDA rules. The commercial outcome depends on:

• Whether the applicant is the first eligible filer.
• Whether the patent holder sues within the statutory period.
• Whether a 30-month stay applies.
• Whether the parties settle.
• Whether the court grants an injunction.
• Whether another applicant can launch under a different certification.
• Whether the product is subject to an approved pediatric exclusivity period.

A Paragraph IV filing does not establish that launch will occur on the earliest theoretical date. Litigation, settlement, regulatory deficiencies, and manufacturing readiness can move the date.

What excipient strategies create commercial opportunities?

1. Generic tablet with a low-cost excipient platform

The simplest opportunity is a conventional immediate-release tablet using widely available excipients. A developer can target:

• Direct compression.
• Robust hardness across six strengths.
• Common film-coating materials.
• Color differentiation by strength.
• Minimal dependence on proprietary excipient grades.
• Efficient scale-up across multiple markets.

The main commercial advantage is manufacturing cost. The main limitation is weak differentiation once several tablet generics enter.

2. Improved oral suspension

A liquid product can command greater strategic value because it serves patients who cannot swallow tablets. Potential development objectives include:

• Lower sedimentation rate.
• Faster redispersion.
• Reduced shaking requirement.
• Better syringe dose accuracy.
• Lower viscosity at the point of administration.
• Improved taste masking.
• Reduced sugar content.
• Alcohol-free positioning.
• Longer in-use stability.
• More convenient bottle and closure design.

The developer must avoid simply copying the reference product’s excipient combination where formulation patent claims remain relevant. A different suspension system could reduce infringement risk, but it must still demonstrate comparable exposure, dose uniformity, microbiological quality, and acceptable stability.

3. Sugar-reduced or sugar-free liquid

Sorbitol contributes sweetness and bulk but can cause gastrointestinal intolerance at higher exposure and may not suit all patients. A sugar-reduced system could use combinations of high-intensity sweeteners, polyols, or taste-masking agents. The commercial target includes pediatric patients, caregivers, and institutional formulary buyers.

A reformulated liquid must manage the interaction between sweeteners, viscosity modifiers, preservative efficacy, and taste. Changing the vehicle can alter drug wetting and sedimentation behavior.

4. Orally disintegrating tablet

An orally disintegrating tablet could target patients with dysphagia without requiring a liquid bottle. Commercial benefits may include:

• Faster administration.
• Reduced need for water.
• Lower shipping and packaging costs than a suspension.
• Better portability.
• Potential use in pediatric and geriatric settings.

Perampanel’s dose range creates a product-design issue. A six-strength ODT portfolio may be expensive, while a single-strength product may require multiple units or tablet splitting. Taste masking would be essential because the tablet disintegrates in the mouth.

5. Multiparticulate or sprinkle formulation

A sprinkle product could allow administration with soft food or through selected feeding systems. This dosage form could compete with the liquid and address patients with swallowing limitations.

The principal technical risks are:

• Uniform drug distribution among particles.
• Release changes after mixing with food.
• Stability after opening.
• Dose recovery from the administration vehicle.
• Accidental exposure from powder handling.
• Need for device-specific instructions.

A multiparticulate product may qualify as a 505(b)(2) opportunity when it materially changes administration or pharmacokinetics.

How strong is the Fycompa patent estate?

Fycompa’s strongest historic protection was the active-ingredient estate. Formulation and method-of-use rights can extend commercial barriers, but their practical strength is narrower.

Patent category	Relative strength	Main vulnerability
Composition of matter	High during unexpired term	Expiration and validity challenges
Tablet formulation	Moderate	Design-around using different excipients or process
Oral-suspension formulation	Moderate to high for liquid competitors	Noninfringement through alternative suspension architecture
Method of use	Variable	Label carve-outs and divided-infringement issues
Manufacturing process	Variable	Independent process development
Dosing-device claims	Low to moderate	Alternative syringe or container design

A generic tablet developer may have a cleaner path than a liquid developer if the tablet does not practice suspension-related claims. A differentiated liquid may produce higher value but requires a more complex freedom-to-operate analysis.

What generic launch scenarios exist for Fycompa?

Scenario 1: Tablet-only generic entry

This is the most direct route. A company enters with one or more strengths, establishes bioequivalence, and expands across the dose range. Price erosion is likely to be rapid once multiple ANDA holders launch.

Scenario 2: Tablet and suspension launch

A dual-format launch increases addressable patients and payer coverage. It also raises manufacturing complexity, stability requirements, and patent exposure.

Scenario 3: First-filer launch followed by liquid competition

The first tablet entrant may capture early volume, while a later liquid entrant builds a narrower but more defensible pediatric and dysphagia franchise.

Scenario 4: 505(b)(2) differentiated product

A new ODT, sprinkle, or taste-masked liquid could support premium pricing or licensing. The applicant would need a clear clinical, administration, or adherence advantage.

How does Fycompa compare with competing antiseizure products?

Fycompa competes with levetiracetam, brivaracetam, lacosamide, lamotrigine, topiramate, and other antiseizure medicines. The commercial comparison is shaped by generic availability, dosing frequency, drug interactions, tolerability, and liquid or pediatric options.

Product	Active ingredient	Generic maturity	Liquid opportunity	Key commercial comparison
Fycompa	Perampanel	Generic-entry potential	High	Once-daily dosing; behavioral and CNS tolerability considerations
Keppra	Levetiracetam	Mature generic market	High	Broad use and strong generic competition
Briviact	Brivaracetam	Later-cycle branded product	Moderate	Differentiated CNS positioning and formulation options
Vimpat	Lacosamide	Generic market developing or established by jurisdiction	Moderate	Oral and injectable formats
Lamictal	Lamotrigine	Mature generic market	Moderate	Broad indications and established pediatric use

Fycompa’s opportunity is strongest where once-daily dosing, liquid administration, or a differentiated pediatric product has value. Its weakness is competition from older, lower-cost generic antiseizure therapies.

What revenue exposure does Fycompa create for Takeda?

Fycompa is a commercial asset within Takeda’s neuroscience portfolio. Public filings discuss product performance at the portfolio level, while standalone Fycompa revenue may not be consistently disclosed.[3] Revenue exposure depends on:

• U.S. generic launch timing.
• Number of approved ANDA holders.
• Price erosion after entry.
• Persistence of branded prescriptions.
• Continued demand for the oral suspension.
• International patent and reimbursement timing.
• Physician use in generalized tonic-clonic seizures.
• Competitive pressure from generic alternatives.

The oral suspension may retain a higher proportion of branded demand than tablets because liquid formulations have fewer suppliers and more difficult manufacturing requirements. That advantage is not permanent if multiple equivalent liquids enter.

What licensing opportunities exist around perampanel formulations?

Licensing opportunities are more likely to involve technology than the active ingredient itself. Relevant assets include:

• Taste-masking platforms.
• Nanocrystal or amorphous-dispersion systems.
• Long-term stable suspension technologies.
• Orally disintegrating matrices.
• Multiparticulate delivery systems.
• Pediatric dosing devices.
• Low-sugar or preservative-reduced liquid systems.
• Global regulatory packages for 505(b)(2) development.

A licensee would typically value a formulation asset based on three factors: freedom to operate against Takeda’s listed patents, evidence of bioequivalence or clinical benefit, and manufacturing scalability. A formulation that only substitutes excipients without improving administration may receive limited commercial value.

Key Takeaways

• Fycompa is perampanel, a small-molecule antiseizure drug available as tablets and oral suspension.
• The tablet formulation uses conventional excipients and is relatively accessible to generic manufacturers.
• The oral suspension has greater technical and commercial defensibility because it requires controlled sedimentation, redispersion, palatability, preservative protection, and dosing accuracy.
• The strongest generic opportunity is a low-cost tablet platform with broad strength coverage.
• The strongest differentiated opportunity is a pediatric-friendly liquid, ODT, or sprinkle formulation.
• Patent risk is highest for products that closely reproduce the reference oral suspension.
• Biosimilar risk does not apply; competition will come from ANDA generics and 505(b)(2) reformulations.
• Orange Book listings, current Paragraph IV activity, patent settlements, and expiration dates require product-specific review before a launch or licensing decision.
• Takeda’s revenue exposure is concentrated in the timing and speed of generic entry, with the liquid product potentially retaining value longer than tablets.

FAQs

Can a generic manufacturer use different excipients from Fycompa?

Yes. A tablet generic can generally use different inactive ingredients if it meets pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. A liquid product must also demonstrate acceptable suspension performance and dose uniformity.

Is Fycompa oral suspension more difficult to copy than Fycompa tablets?

Yes. The suspension requires control of particle wetting, viscosity, sedimentation, redispersion, preservative performance, palatability, and dosing-device accuracy. These requirements increase development and manufacturing risk.

Could a perampanel ODT obtain a premium price?

Potentially. An ODT could target dysphagia and portability, but premium pricing would depend on regulatory pathway, patent position, payer acceptance, taste performance, and whether multiple competitors already offer equivalent administration benefits.

Does changing the preservative avoid a Fycompa formulation patent?

Not necessarily. Patent claims may cover broader excipient combinations, concentration ranges, pH conditions, or functional properties. A preservative change must be assessed against the full claim set.

Is perampanel suitable for a fixed-dose combination product?

Perampanel could theoretically be combined with another antiseizure drug, but clinical justification, dose flexibility, drug-interaction considerations, titration requirements, and regulatory requirements would limit the commercial case.

References

1. U.S. Food and Drug Administration. (2023). Fycompa (perampanel) prescribing information. Eisai Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

3. Takeda Pharmaceutical Company Limited. (2024). Annual report and financial results materials. https://www.takeda.com/financial-results/